DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
STVN logo

Stevanato Group S.p.A. Stock Price

NYSE:STVN Community·US$5.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

STVN Share Price Performance

US$21.51
-5.42 (-20.13%)
​
US$24.39
Fair Value
US$21.51
-5.42 (-20.13%)
11.8% undervalued intrinsic discount
US$24.39
Fair Value
Price US$21.51
AnalystConsensusTarget US$24.39
AnalystHighTarget US$32.00
AnalystLowTarget US$20.00
Mon, 15 Jun 26
Fair ValueUS$24.39
Share Pricen/a

STVN Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$24.39 11.8% undervalued intrinsic discount

US Onshoring And Rising Biologics Demand Will Reshape Drug Delivery

1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$32 32.8% undervalued intrinsic discount

Automation And Biologics Adoption Will Transform Injectable Solutions

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$20 7.6% overvalued intrinsic discount

Rising Regulatory Costs And Local Rivalry Will Compress Margins

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
STVN logo
Stevanato Group
11.8% undervalued intrinsic discount

US Onshoring And Rising Biologics Demand Will Reshape Drug Delivery

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 15 Jun
Read Narrative
STVN logo
Stevanato Group
7.6% overvalued intrinsic discount

Rising Regulatory Costs And Local Rivalry Will Compress Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 5 Aug
Read Narrative
STVN logo
Stevanato Group
32.8% undervalued intrinsic discount

Automation And Biologics Adoption Will Transform Injectable Solutions

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 26 Mar
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
STVN logo

STVN: Biologics And GLP-1 Demand Will Support Execution And Cash Flow

Fair Value: US$20 7.6% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
STVN logo

STVN: GLP-1 Exposure And Biologics Focus Will Support Future Earnings Power

Fair Value: US$24.39 11.8% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
STVN logo

STVN: Biologics Focus And On Body Delivery Collaboration Will Drive Future Cash Flows

Fair Value: US$32 32.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and slightly overvalued.

0 Risks
3 Rewards
View Full Analysis

Stevanato Group S.p.A. Key Details

€1.2b

Revenue

€865.0m

Cost of Revenue

€360.2m

Gross Profit

€225.6m

Other Expenses

€134.6m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.49
29.40%
10.99%
28.0%
View Full Analysis

About STVN

Founded
1949
Employees
6010
CEO
Franco Stevanato
WebsiteView website
www.stevanatogroup.com

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Recent STVN News & Updates

Seeking Alpha • Aug 29

Stevanato Group: Alina Validates The Container-To-Device Flywheel

Summary Stevanato Group is transforming from a pharmaceutical glass supplier into an integrated drug containment and delivery platform, validated by commercial adoption of its Alina injector. High-value solutions now drive 45% of revenue, growing 16% year-over-year, with recent capacity investments in Fishers and Latina expected to boost operating leverage and margin expansion. STVN is shifting its portfolio toward premium, integrated offerings, divesting low-margin assets like Balda and focusing on durable, higher-margin customer relationships. Execution risk remains, particularly with customer validation timelines and GLP-1 revenue concentration, but ramping new facilities and restored free cash flow could re-rate STVN as a drug-delivery infrastructure platform. Read the full article on Seeking Alpha
User avatar
Narrative Update • Aug 05

STVN: Biologics And GLP-1 Demand Will Support Execution And Cash Flow

Analysts have raised their fair value estimate for Stevanato Group to $20.00 from $17.50, citing recent Street research that highlights the company’s move up the value chain into higher value biologics related containment solutions and its exposure to GLP-1 driven demand as key supports for higher future P/E assumptions. Analyst Commentary on Stevanato Group Recent Street research around Stevanato Group points to a company that is moving further into higher value biologics related containment, with growing exposure to GLP-1 related demand.

Recent updates

No updates

Stevanato Group S.p.A. Competitors

TEVA logo

Teva Pharmaceutical Industries

Symbol: NYSE:TEVA
Market cap: US$45.4b
A logo

Agilent Technologies

Symbol: NYSE:A
Market cap: US$44.1b
IQV logo

IQVIA Holdings

Symbol: NYSE:IQV
Market cap: US$43.9b
WAT logo

Waters

Symbol: NYSE:WAT
Market cap: US$41.4b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide